NASDAQ:LMAT

LeMaitre Vascular (LMAT) Stock Forecast, Price & News

$55.16

+0.68 (+1.25%)

(As of 10/2/2023 ET)

Compare

Today's Range: $53.91
▼
$55.20
50-Day Range: $53.45
▼
$64.70
52-Week Range: $41.78
▼
$68.67

Volume: 197,500 shs
Average Volume: 112,778 shs
Market Capitalization: $1.23 billion

P/E Ratio: 48.81
Dividend Yield: 1.02%
Price Target: $69.50

LeMaitre Vascular MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 26.0% Upside
$69.50 Price Target
Short Interest: Bearish
3.13% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: N/A
News Sentiment: 1.08
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 17.83%
From $1.29 to $1.52 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.07 out of 5 stars

Medical Sector

28th out of 975 stocks

Surgical & Medical Instruments Industry

6th out of 101 stocks

3.3

Analyst's Opinion

Consensus Rating
LeMaitre Vascular has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $69.50, LeMaitre Vascular has a forecasted upside of 26.0% from its current price of $55.16.
Amount of Analyst Coverage
LeMaitre Vascular has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.13% of the float of LeMaitre Vascular has been sold short.
Short Interest Ratio / Days to Cover
LeMaitre Vascular has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in LeMaitre Vascular has recently increased by 7.66%, indicating that investor sentiment is decreasing significantly.

4.2

Dividend Strength

Dividend Yield
LeMaitre Vascular pays a meaningful dividend of 1.03%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
LeMaitre Vascular has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of LeMaitre Vascular is 49.56%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 36.84% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LMAT.

2.8

News and Social Media Coverage

News Sentiment
LeMaitre Vascular has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for LeMaitre Vascular this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for LMAT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, LeMaitre Vascular insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.50% of the stock of LeMaitre Vascular is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for LeMaitre Vascular are expected to grow by 17.83% in the coming year, from $1.29 to $1.52 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of LeMaitre Vascular is 48.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.43.
Price to Earnings Ratio vs. Sector
The P/E ratio of LeMaitre Vascular is 48.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.55.
Price to Earnings Growth Ratio
LeMaitre Vascular has a PEG Ratio of 5.27. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
LeMaitre Vascular has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LMAT Price History

30 days | 90 days | 365 days | Advanced Chart

LMAT Stock News Headlines

September 30, 2023 | americanbankingnews.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 21, 2023 | markets.businessinsider.com

Positive Growth Prospects and Favorable Pricing Strategy Boost Lemaitre Vascular’s Buy Rating: An Analysis by Michael Petusky

October 3, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 19, 2023 | finance.yahoo.com

Capital Allocation Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Ideal

September 7, 2023 | msn.com

Oppenheimer Initiates Coverage of Lemaitre Vascular (LMAT) with Outperform Recommendation

September 6, 2023 | markets.businessinsider.com

Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating

September 1, 2023 | finance.yahoo.com

Looking for Dividend Growth? Buy This Little-Known Healthcare Stock

August 26, 2023 | finance.yahoo.com

A Look At The Intrinsic Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

October 3, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 24, 2023 | msn.com

LeMaitre: Record Quarter, ASPs And Volumes Ratcheting Higher Equals Qualified Growth Outlook

August 12, 2023 | finance.yahoo.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Pays A US$0.14 Dividend In Just Three Days

August 9, 2023 | finance.yahoo.com

Here’s Why LeMaitre Vascular (LMAT) Outperformed in Q2

August 3, 2023 | insidermonkey.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2023 Earnings Call Transcript

August 3, 2023 | finance.yahoo.com

Here's Why We Think LeMaitre Vascular (NASDAQ:LMAT) Might Deserve Your Attention Today

August 2, 2023 | finanznachrichten.de

LeMaitre Vascular, Inc.: LeMaitre Q2 2023 Financial Results

August 2, 2023 | finance.yahoo.com

Q2 2023 LeMaitre Vascular Inc Earnings Call

August 1, 2023 | finance.yahoo.com

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates

August 1, 2023 | finance.yahoo.com

LeMaitre Q2 2023 Financial Results

July 31, 2023 | finance.yahoo.com

LeMaitre to Present at Upcoming Investor Conferences in August

July 21, 2023 | finance.yahoo.com

LMAT - LeMaitre Vascular, Inc.

July 17, 2023 | finance.yahoo.com

LeMaitre Will Announce Second Quarter 2023 Earnings Results August 1, 2023

June 21, 2023 | fool.com

LeMaitre Vascular (NASDAQ: LMAT)

June 15, 2023 | finance.yahoo.com

Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?

June 14, 2023 | seekingalpha.com

LeMaitre: Continues To Create Value, Breakout To New Highs

June 6, 2023 | finance.yahoo.com

LeMaitre to Present at Upcoming Investor Conferences in June

May 31, 2023 | finance.yahoo.com

LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why

May 27, 2023 | finance.yahoo.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

See More Headlines

Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

LMAT Company Calendar

Last Earnings: 8/01/2023
Ex-Dividend for 8/31 Dividend: 8/16/2023
Dividend Payable: 8/31/2023
Today: 10/03/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LMAT
CUSIP: N/A
CIK: 1158895
Web: www.lemaitre.com
Phone: (781) 221-2266
Fax: 781-425-5049
Employees: 591
Year Founded: 1983

Price Target and Rating

Average Stock Price Forecast: $69.50
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $66.00
Forecasted Upside/Downside: +26.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.13
Trailing P/E Ratio: 48.81
Forward P/E Ratio: 42.76
P/E Growth: 5.27
Net Income: $20.64 million
Net Margins: 14.23%
Pretax Margin: 18.22%
Return on Equity: 9.33%
Return on Assets: 8.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.75
Quick Ratio: 4.67

Sales & Book Value

Annual Sales: $161.65 million
Price / Sales: 7.60
Cash Flow: $1.52 per share
Price / Cash Flow: 36.38
Book Value: $12.19 per share
Price / Book: 4.53

Miscellaneous

Outstanding Shares: 22,260,000
Free Float: 19,480,000
Market Cap: $1.23 billion
Optionable: Optionable
Beta: 0.98

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. George W. LeMaitre (Age 58)
Chairman & CEO
Comp: $840.11k

Mr. David B. Roberts (Age 59)
Pres & Director
Comp: $522.32k

Mr. Joseph P. Pellegrino Jr. (Age 58)
CFO, Treasurer, Sec. & Director
Comp: $463.58k

Mr. Trent G. Kamke (Age 52)
Sr. VP of Operations
Comp: $417.83k

Dr. George D. LeMaitre (Age 89)
Founder and Chairman of Scientific Advisory Board

Mr. David C. Hissong
Gen. Counsel

Ms. Kimberly L. Cieslak (Age 50)
VP of Marketing

Mr. Daniel J. Mumford (Age 41)
Director of HR

Mr. Ryan H. Connelly (Age 46)
Sr. VP of Advanced Manufacturing Engineering

Mr. Andrew Hodgkinson (Age 47)
Sr. VP of Clinical, Regulatory & Quality Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LMAT Stock - Frequently Asked Questions

Should I buy or sell LeMaitre Vascular stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LMAT shares.
View LMAT analyst ratings or view top-rated stocks.
What is LeMaitre Vascular's stock price forecast for 2023?: 5 brokers have issued 12 month price targets for LeMaitre Vascular's stock. Their LMAT share price forecasts range from $66.00 to $75.00. On average, they anticipate the company's share price to reach $69.50 in the next year. This suggests a possible upside of 26.0% from the stock's current price.
View analysts price targets for LMAT or view top-rated stocks among Wall Street analysts.
How have LMAT shares performed in 2023?: LeMaitre Vascular's stock was trading at $46.02 at the beginning of 2023. Since then, LMAT shares have increased by 19.9% and is now trading at $55.16.
View the best growth stocks for 2023 here.
When is LeMaitre Vascular's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our LMAT earnings forecast.
How were LeMaitre Vascular's earnings last quarter?: LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its quarterly earnings data on Tuesday, August, 1st. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.32 by $0.05. The medical instruments supplier earned $50.12 million during the quarter, compared to analysts' expectations of $48.29 million. LeMaitre Vascular had a net margin of 14.23% and a trailing twelve-month return on equity of 9.33%.
How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?: LeMaitre Vascular announced a quarterly dividend on Tuesday, July 25th. Investors of record on Thursday, August 17th will be given a dividend of $0.14 per share on Thursday, August 31st. This represents a $0.56 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Wednesday, August 16th.
Read our dividend analysis for LMAT.
What ETFs hold LeMaitre Vascular's stock?: ETFs with the largest weight of LeMaitre Vascular (NASDAQ:LMAT) stock in their portfolio include Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Micro-Cap ETF (IWC).iShares U.S. Medical Devices ETF (IHI).
Is LeMaitre Vascular a good dividend stock?: LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.56 per share and currently has a dividend yield of 1.03%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 49.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 36.84% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

What guidance has LeMaitre Vascular issued on next quarter's earnings?: LeMaitre Vascular issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $0.28-$0.33 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $46.50 million-$48.90 million, compared to the consensus revenue estimate of $45.91 million.
What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?: 13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of LeMaitre Vascular own?: Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).
What is LeMaitre Vascular's stock symbol?: LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."
How do I buy shares of LeMaitre Vascular?: Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is LeMaitre Vascular's stock price today?: One share of LMAT stock can currently be purchased for approximately $55.16.
How much money does LeMaitre Vascular make?: LeMaitre Vascular (NASDAQ:LMAT) has a market capitalization of $1.23 billion and generates $161.65 million in revenue each year. The medical instruments supplier earns $20.64 million in net income (profit) each year or $1.13 on an earnings per share basis.
How many employees does LeMaitre Vascular have?: The company employs 591 workers across the globe.
Does LeMaitre Vascular have any subsidiaries?: The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.
Read More
How can I contact LeMaitre Vascular?: LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The official website for the company is www.lemaitre.com. The medical instruments supplier can be reached via phone at (781) 221-2266 or via fax at 781-425-5049.

This page (NASDAQ:LMAT) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial